Expected Evolution of COVID-19 Epidemic in France for Several Combinations of Vaccination Strategies and Barrier Measures
Simon Pageaud,
Catherine Pothier,
Christophe Rigotti,
Anne Eyraud-Loisel,
Jean-Pierre Bertoglio,
Alexis Bienvenüe,
Nicolas Leboisne,
Nicolas Ponthus,
Romain Gauchon,
François Gueyffier,
Philippe Vanhems,
Jean Iwaz,
Stéphane Loisel,
Pascal Roy,
on behalf of the Group CovDyn (Covid Dynamics)
Affiliations
Simon Pageaud
Université de Lyon, F-69000 Lyon, France
Catherine Pothier
CNRS UMR 5205, Laboratoire d’InfoRmatique en Image et Systèmes d’Information (LIRIS), F-69621 Villeurbanne, France
Christophe Rigotti
CNRS UMR 5205, Laboratoire d’InfoRmatique en Image et Systèmes d’Information (LIRIS), F-69621 Villeurbanne, France
Anne Eyraud-Loisel
Laboratoire de Sciences Actuarielle et Financière (LSAF), Institut de Science Financière et d’Assurances (ISFA), Université Claude Bernard Lyon 1, F-69007 Lyon, France
Jean-Pierre Bertoglio
CNRS UMR 5509, Laboratoire de Mécanique des Fluides et d’Acoustique (LMFA), F-69130 Ecully, France
Alexis Bienvenüe
Laboratoire de Sciences Actuarielle et Financière (LSAF), Institut de Science Financière et d’Assurances (ISFA), Université Claude Bernard Lyon 1, F-69007 Lyon, France
Nicolas Leboisne
Laboratoire de Sciences Actuarielle et Financière (LSAF), Institut de Science Financière et d’Assurances (ISFA), Université Claude Bernard Lyon 1, F-69007 Lyon, France
Nicolas Ponthus
École Centrale de Lyon, F-69130 Lyon, France
Romain Gauchon
Laboratoire de Sciences Actuarielle et Financière (LSAF), Institut de Science Financière et d’Assurances (ISFA), Université Claude Bernard Lyon 1, F-69007 Lyon, France
François Gueyffier
Université de Lyon, F-69000 Lyon, France
Philippe Vanhems
Service d’Hygiène, Épidémiologie, Infectiovigilance et Prévention, Hôpital Edouard Herriot, Hospices Civils de Lyon, F-69003 Lyon, France
Jean Iwaz
Université de Lyon, F-69000 Lyon, France
Stéphane Loisel
Laboratoire de Sciences Actuarielle et Financière (LSAF), Institut de Science Financière et d’Assurances (ISFA), Université Claude Bernard Lyon 1, F-69007 Lyon, France
The outbreak of the SARS-CoV-2 virus, enhanced by rapid spreads of variants, has caused a major international health crisis, with serious public health and economic consequences. An agent-based model was designed to simulate the evolution of the epidemic in France over 2021 and the first six months of 2022. The study compares the efficiencies of four theoretical vaccination campaigns (over 6, 9, 12, and 18 months), combined with various non-pharmaceutical interventions. In France, with the emergence of the Alpha variant, without vaccination and despite strict barrier measures, more than 600,000 deaths would be observed. An efficient vaccination campaign (i.e., total coverage of the French population) over six months would divide the death toll by 10. A vaccination campaign of 12, instead of 6, months would slightly increase the disease-related mortality (+6%) but require a 77% increase in ICU bed–days. A campaign over 18 months would increase the disease-related mortality by 17% and require a 244% increase in ICU bed–days. Thus, it seems mandatory to vaccinate the highest possible percentage of the population within 12, or better yet, 9 months. The race against the epidemic and virus variants is really a matter of vaccination strategy.